GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Chengdu Easton Biopharmaceuticals Co Ltd (SHSE:688513) » Definitions » Equity-to-Asset

Chengdu Easton Biopharmaceuticals Co (SHSE:688513) Equity-to-Asset : 0.78 (As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Chengdu Easton Biopharmaceuticals Co Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Chengdu Easton Biopharmaceuticals Co's Total Stockholders Equity for the quarter that ended in Mar. 2024 was ¥2,626 Mil. Chengdu Easton Biopharmaceuticals Co's Total Assets for the quarter that ended in Mar. 2024 was ¥3,374 Mil. Therefore, Chengdu Easton Biopharmaceuticals Co's Equity to Asset Ratio for the quarter that ended in Mar. 2024 was 0.78.

The historical rank and industry rank for Chengdu Easton Biopharmaceuticals Co's Equity-to-Asset or its related term are showing as below:

SHSE:688513' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.71   Med: 0.8   Max: 0.85
Current: 0.78

During the past 8 years, the highest Equity to Asset Ratio of Chengdu Easton Biopharmaceuticals Co was 0.85. The lowest was 0.71. And the median was 0.80.

SHSE:688513's Equity-to-Asset is ranked better than
64.08% of 1559 companies
in the Biotechnology industry
Industry Median: 0.67 vs SHSE:688513: 0.78

Chengdu Easton Biopharmaceuticals Co Equity-to-Asset Historical Data

The historical data trend for Chengdu Easton Biopharmaceuticals Co's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chengdu Easton Biopharmaceuticals Co Equity-to-Asset Chart

Chengdu Easton Biopharmaceuticals Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Equity-to-Asset
Get a 7-Day Free Trial 0.71 0.83 0.83 0.81 0.78

Chengdu Easton Biopharmaceuticals Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.81 0.81 0.80 0.78 0.78

Competitive Comparison of Chengdu Easton Biopharmaceuticals Co's Equity-to-Asset

For the Biotechnology subindustry, Chengdu Easton Biopharmaceuticals Co's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Chengdu Easton Biopharmaceuticals Co's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Chengdu Easton Biopharmaceuticals Co's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Chengdu Easton Biopharmaceuticals Co's Equity-to-Asset falls into.



Chengdu Easton Biopharmaceuticals Co Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Chengdu Easton Biopharmaceuticals Co's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )=Total Stockholders Equity/Total Assets
=2603.42/3346.754
=0.78

Chengdu Easton Biopharmaceuticals Co's Equity to Asset Ratio for the quarter that ended in Mar. 2024 is calculated as

Equity to Asset (Q: Mar. 2024 )=Total Stockholders Equity/Total Assets
=2626.11/3374.371
=0.78

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Chengdu Easton Biopharmaceuticals Co  (SHSE:688513) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Chengdu Easton Biopharmaceuticals Co Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Chengdu Easton Biopharmaceuticals Co's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Chengdu Easton Biopharmaceuticals Co (SHSE:688513) Business Description

Traded in Other Exchanges
N/A
Address
No. 8, Xiyuan Avenue, Chengdu High-tech Zone, Sichuan Province, Chengdu, CHN, 611731
Chengdu Easton Biopharmaceuticals Co Ltd is engaged in research and development, production and sales of chemical raw materials and chemical pharmaceutical preparations. The company's products range from Active Pharmaceutical Ingredient to finish dosage forms like capsules, tablets and injections, enabling us to take R&D discovery to industrial level, solving problems during the course of R&D, production and distribution. Its products are categorized under Active Pharmaceutical Ingredients and Fixed Dose Formulation.

Chengdu Easton Biopharmaceuticals Co (SHSE:688513) Headlines

No Headlines